Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 1.06M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -845.61M | Forward P/E | -0.02 | EPS next Y | - | 50D Avg Chg | -84.00% |
| Sales | 13.15M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 0.11 | EPS next 5Y | 57.80% | 52W High Chg | -100.00% |
| Recommedations | 5.00 | Quick Ratio | 1.65 | Shares Outstanding | 35.31M | 52W Low Chg | 14,900.00% |
| Insider Own | - | ROA | -88.16% | Shares Float | 28.33M | Beta | 0.81 |
| Inst Own | 3.79% | ROE | -251.34% | Shares Shorted/Prior | 841.51K/1.10M | Price | 0.03 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 69,580 | Target Price | 1.00 |
| Oper. Margin | -5,922.12% | Earnings Date | - | Volume | 23,208 | Change | -62.50% |
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.